HLA Class I Bw4, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-HLA Class I Bw4, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | HLA Class I Bw4, Human |
| Clone | REA274 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | fluorescein (FITC) conjugate |
| Size | 30 tests in 300 µL |
| Concentration | 1:11 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | HLA Class I Bw4 Antibody, anti-human, FITC, REAfinity™. Clone REA274 recognizes HLA Bw4, a class I human leukocyte antigen (HLA). Expressed on the surface of most nucleated cells, class I molecules are heterodimeric molecules and consist of a type I integral membrane α heavy chain and soluble β2 microglobulin protein. The extracellular region of the heavy chain further consists of three domains, one of which comprises the peptide binding groove. Antigens binding to class I molecules are 8-10 amino acids long and play an important role in recognition of the virus infected and malignant cells by cytotoxic T lymphocytes (CTLs). In addition, class I molecules interact with NK cell receptors to modulate the activity of NK cells. Analysis of HIV-infected patients found the combination of the NK cell receptor KIR3DS1/L1 and a presumptive HLA Bw4 ligand to be correlated with slower progression to AIDS. | Additional information: Clone REA274 displays negligible binding to Fc receptors. | |
| Immunogen | n/a |
| Other Names | HLA-B, AS, SPDA1 |
| Gene, Accession # | Gene ID: 3106 |
| Catalog # | 130-103-916 |
| Price | $93 |
| Order / More Info | HLA Class I Bw4, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Carr, W. H. et al. (2005) KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 175 (8): 5222-5229. | Hewitt, E. W. et al. (2003) The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110 (2): 163-169. | Martin, M. P. et al. (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39 (6): 733-740. | Garrido, C. et al. (2016) HIV latency-reversing agents have diverse effects on natural killer cell function. Front Immunol 7: 356. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies